Curis Inc. (NASDAQ:CRIS) has been given a $7.00 target price by investment analysts at RBC Capital Markets in a note issued to investors on Wednesday. The brokerage currently has a a “buy” rating on the stock. RBC Capital Markets’ price target indicates a potential upside of 131.02% from the stock’s current price.

Several other analysts have also recently commented on the company. Zacks Investment Research raised Curis from a “sell” rating to a “hold” rating in a report on Monday, September 19th. Robert W. Baird reissued an “outperform” rating and issued a $7.00 price target on shares of Curis in a report on Wednesday, September 7th. Finally, FBR & Co reissued a “buy” rating on shares of Curis in a report on Thursday, September 8th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $5.05.

Analyst Recommendations for Curis (NASDAQ:CRIS)

Shares of Curis (NASDAQ:CRIS) traded down 1.32% during mid-day trading on Wednesday, reaching $2.99. The company’s stock had a trading volume of 398,057 shares. The company’s 50-day moving average is $2.26 and its 200 day moving average is $1.87. The firm’s market capitalization is $387.12 million. Curis has a 1-year low of $1.25 and a 1-year high of $3.42.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Curis (NASDAQ:CRIS) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.09) EPS for the quarter, meeting the consensus estimate of ($0.09). The business earned $1.70 million during the quarter, compared to analysts’ expectations of $2.05 million. Curis had a negative return on equity of 65.51% and a negative net margin of 526.72%. The company’s quarterly revenue was down 19.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.06) EPS. On average, analysts expect that Curis will post ($0.37) earnings per share for the current year.

In related news, major shareholder Discovery Technologie Aurigene purchased 10,208,333 shares of the company’s stock in a transaction on Wednesday, September 7th. The stock was bought at an average price of $2.40 per share, with a total value of $24,499,999.20. Following the completion of the transaction, the insider now owns 27,328,464 shares of the company’s stock, valued at approximately $65,588,313.60. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 6.09% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in CRIS. Barclays PLC increased its position in Curis by 10,149.4% in the second quarter. Barclays PLC now owns 64,059 shares of the company’s stock valued at $100,000 after buying an additional 63,434 shares during the last quarter. Metropolitan Life Insurance Co. NY bought a new position in Curis during the second quarter valued at $146,000. ProShare Advisors LLC increased its position in Curis by 1.3% in the second quarter. ProShare Advisors LLC now owns 109,812 shares of the company’s stock valued at $171,000 after buying an additional 1,418 shares during the last quarter. Rhumbline Advisers increased its position in Curis by 27.2% in the second quarter. Rhumbline Advisers now owns 138,986 shares of the company’s stock valued at $217,000 after buying an additional 29,751 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new position in Curis during the first quarter valued at $248,000. 52.36% of the stock is owned by institutional investors.

Curis Company Profile

Curis, Inc is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes.

5 Day Chart for NASDAQ:CRIS

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with's FREE daily email newsletter.